Vice President, Medical - IBD

h3Vice President Medical - Inflammatory Bowel Disease (IBD) /h3 pbLocation: /b Remote (Europe) / Horgen, Switzerland / United Kingdom /p pbReporting to: /b SVP Development Operations /p h3Company Context /h3 pNumab Therapeutics AG is a Swiss‑headquartered biotechnology company based in Horgen, Zurich canton, dedicated to developing multi‑specific antibody‑based immunotherapies for cancer and inflammation. Using its proprietary λ‑Cap™ and MATCH™ technology platforms, Numab designs and engineers multi‑specific antibodies that combine best‑in‑class potency, stability, and pharmacokinetic properties. The company has built a broad and differentiated pipeline of in‑house programs across immunology and oncology, and has established multiple collaborations with leading global pharmaceutical partners—underlining the scalability and external validation of its platform and business model. In 2024 the company completed a major transaction with Johnson Johnson through the sale of its subsidiary (Yellow Jersey Therapeutics) which included rights to NM26‑2198 in a deal valued at approximately USD1.25billion. In early 2025, the Series C fundraising was extended to CHF180million to support several first- and best-in‑class programs. With a headcount of around 80 employees, Numab now enters an exciting phase of development. /p h3Role Purpose /h3 pThe Vice President, Medical will play a dual role spanning Clinical Development and Medical Affairs. Internally, they will provide medical leadership for the ongoing development of Numab's IBD programme, contributing to clinical strategy, trial design, data interpretation, and development planning. A key focus will be helping shape the design of early phase studies in patients and identifying innovative approaches that maximize the opportunity to demonstrate meaningful clinical differentiation in a competitive therapeutic landscape. Externally, they will establish and maintain trusted relationships with leading experts in IBD and related fields, helping ensure that Numab's science, data, and therapeutic approach are understood within the broader context of disease biology and evolving treatment paradigms. The individual will serve as a credible scientific ambassador for the company and play an important role in shaping external scientific dialogue surrounding both the programme and the future role of tri‑specific antibodies in IBD. /p h3Key Responsibilities /h3 h3Clinical Development /h3 ul liContribute to the overall clinical development strategy for Numab's IBD programme. /li liPartner closely with Clinical Operations, Translational Medicine, Regulatory Affairs, and Executive Leadership to advance development plans. /li liProvide medical leadership and strategic input into Phase IIb study design and future development strategy. /li liIdentify creative and scientifically rigorous approaches to trial design, endpoint selection, patient segmentation, biomarker integration, and evidence generation. /li liIncorporate insights from clinical practice, scientific experts, and the competitive landscape to optimize development plans. /li liEvaluate emerging clinical and translational data and provide strategic recommendations to guide programme decisions. /li liContribute to protocol development, protocol amendments, investigator-facing scientific materials, and study governance discussions. /li liSupport benefit-risk assessment and interpretation of efficacy and safety findings throughout development. /li /ul h3Medical Affairs External Scientific Leadership /h3 ul liLead external scientific engagement activities for Numab's IBD programme. /li liBuild and maintain strong relationships with key opinion leaders, investigators, academic experts, and scientific societies. /li liFacilitate scientific exchange regarding disease biology, treatment paradigms, emerging evidence, and the potential role of novel therapeutic approaches in IBD. /li liHelp establish and communicate the scientific narrative surrounding Numab's programme and its differentiated therapeutic approach. /li liGenerate external insights that inform development strategy, evidence generation plans, and future positioning. /li liRepresent Numab at scientific congresses, advisory boards, investigator meetings, and other external forums. /li liContribute to publications, scientific communications, and educational initiatives. /li liAct as a trusted scientific representative for the company with clinical, scientific, and investment stakeholders. /li /ul h3Key Qualifications Experience /h3 ul liMD or equivalent medical qualification. /li liSignificant experience within biotechnology or pharmaceutical drug development. /li liDeep expertise in inflammatory bowel disease, with an established reputation and network within the IBD community. /li liExperience spanning both Medical Affairs and Clinical Development. /li liStrong understanding of inflammatory pathways, disease pathophysiology, biologic therapies, and evolving treatment approaches in IBD. /li liDemonstrated experience contributing to clinical study design, development strategy, and interpretation of clinical data. /li liProven ability to engage and influence scientific discussions with external experts through credible, evidence‑based scientific exchange. /li /ul h3Key Competencies /h3 ul liChallenges assumptions and contributes to decision‑making /li liThrives in a fast‑paced environment /li liStrong strategic thinking skills with the ability to translate scientific insights into development and business decisions. /li liOutstanding communication and presentation skills. /li /ul h3Posting details /h3 pApplication deadline is bThursday 2nd July /b. /p pNumab are based in Horgen, Switzerland. This role can be conducted remotely from Europe, with occasional travel to the Numab office. /p #J-18808-Ljbffr